Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAL trial of pembrolizumab maintenance de-escalation in stage IV NSCLC
2024-515945-40-00Phase 3Authorised
- Sponsor
- IFCT
- Start
- May 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Maintenance pembrolizumab until progression with Observation after induction (2 arms). Primary endpoints: 18-month overall survival and Overall survival. Planned start May 2022; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-515945-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515945-40-00.